- Poster presentation
- Open Access
Toward a serum-free, xeno-free culture system for optimal growth and expansion of hMSC suited to therapeutic applications
© Genser-Nir et al.; licensee BioMed Central Ltd. 2013
- Published: 4 December 2013
- Multilineage Differentiation
- Multilinage Differentiation Potential
- Phenotypic Surface Marker
- Recombinant Trypsin
- hMSC Proliferation
Human mesenchymal stem cells (hMSC) hold great promise as a tool in regenerative medicine and cell therapy. Application of hMSC in cell therapy requires the elaboration of an appropriate serum-free (SF), xeno-free (XF) culture system in order to minimize the health risk of using xenogenic compounds, and to limit the immunological reactions in-vivo. Besides the well-known disadvantages of serum, in comparison to a SF, XF culture system, serum also exhibits poor performance in the context of hMSC proliferation. In the present study, a novel SF, XF culture system for hMSC suitable for therapeutic applications was developed and evaluated. The SF, XF culture system includes specially developed solutions for attachment, dissociation, and freezing, as well as a culture medium, MSC NutriStem® XF, that enables long-term growth of multipotent hMSC. Development of the SF, XF culture system was conducted on hMSC from a variety of sources: bone marrow (BM), adipose tissue (AT) and Wharton's jelly (WJ).
MSC NutriStem® XF culture medium was examined in combination with MSC Attachment Solution (BI, 05-752-1) and either Recombinant Trypsin Solution (BI, 03-078-1) or MSC Dissociation Solution (BI, 03-075-1). The performance of MSC NutriStem® XF was evaluated based on the following parameters: proliferation rate, viability, morphology, stemness (estimated from CFU-F), multilineage differentiation capability, and phenotypic surface marker profile .
hMSC (passage 1-5) from a variety of sources: BM (Lonza, Promocell), AT (Promocell, ATCC), and WJ (ATCC, Prof. Mark Weiss - self isolation) were used in this study.
hMSC were cultured in a SF, XF expansion medium (MSC NutriStem® XF, BI) on pre-coated dishes (MSC Attachment Solution, BI) or other media; commercial SF media (Invitrogen; SCT, Promocell), in-house serum-containing formulation (Prof. Mark Weiss). Cells were seeded at 5000-6000 viable cells/cm2, and harvested using either MSC Dissociation Solution (BI) or recombinant Trypsin Dissociation Solution (BI).
Medium performance evaluation
Medium performance was evaluated by conducting a comparison of proliferation rate, cell morphology, multilinage differentiation potential into adipocytes, osteocytes, and chondrocytes, self-renewal potential and cell immunophenotype.
Cell proliferation was assessed by cell count using a trypan blue exclusion assay at each time point.
hMSC expanded for 3-5 passages in MSC NutriStem® XF were tested for maintenance of multilineage differentiation potential (into adipocytes, osteocytes, and chondrocytes) using in-house differentiation formulations. Undifferentiated control cells were cultured in MSC NutriStem® XF. Cells were fixed and stained with Oil Red O, Alizarin Red/von Kossa, and Alcian blue/Masson's trichrome, respectively.
hMSC were seeded at low densities (10, 50, and 100 cells/cm2) in MSC NutriStem® XF, cultured for 14 days, and stained with 0.5% crystal violet.
WJ-derived hMSC were cultured for five passages in MSC NutriStem® XF, followed by immunophenotype evaluation by flow cytometry expression of CD73, CD90, CD105, HLA-ABC (positive), HLA-DR, and CD45 (negative).
The use of serum is not an option from a regulatory point of view. A SF, XF culture system for hMSC was developed and enables long-term growth of multipotent hMSC suitable for therapeutic applications. The performance of MSC NutriStem® XF medium was proved to be superior to serum-containing medium and commercially available SF media. MSC NutriStem® XF medium supports long-term culture of hMSC from a variety of sources, while retaining the essential hMSC characteristics (fibroblast-like morphology, surface markers phenotype, multilineage differentiation, and self-renewal potential).The developed SF, XF culture system (MSC NutriStem® XF medium, MSC Attachment Solution, either MSC Dissociation Solution or Recombinant Trypsin solution, and MSC Freezing Solution) supports the expansion of hMSC suitable for clinical applications.
We would like to thank Professor Mark L. Weiss, Kansas State University, Department of Anatomy and Physiology, Manhattan, KS, for his invaluable contribution to this study.
- Poster: ISCT 2012 Seattle, USA. Identification of optimal conditions for generating MSCs for preclinical testing: Comparison of three commercial serum-free media and low-serum growth medium. Edited by: Yelica López, Elizabeth Trevino, Mark L. Weiss, Kansas State University, Department of Anatomy and Physiology, Manhattan, KSGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.